Presentation is loading. Please wait.

Presentation is loading. Please wait.

Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab.

Published byGeorgiana Gallagher Modified over 8 years ago

Similar presentations

Presentation on theme: "Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab."— Presentation transcript:

1 Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60–90 and RI: 30–60 subjects AUC: area under the concentration–time curve from zero to infinity RI: renally impaired

2 Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60–90 and RI: 30–60 subjects

3 Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab in middle-aged, elderly, RI: 60–90 and RI: 30–60 subjects

Download ppt "Based on: Glund S et al., Clin Pharmacokinet 2016 Pharmacokinetics of idarucizumab Pharmacokinetics of idarucizumab following administration of idarucizumab."

Similar presentations

Proton Pump Inhibitor (PPI) Studies

Proton Pump Inhibitor (PPI) Studies
Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.

Area under the plasma concentration time curve. IMPORTANCE OF AUC Pharmacokinetics - measurement of bioavaibility absolute, relative Biopharmaceutics.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.

Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:587-92.

Definition of measurements and patients Michael J. Murphy, et al. Br J Clin Pharmacol 2008;65:
Mega JL, et al. N Engl J Med 2009;360:354-62. Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.

Mega JL, et al. N Engl J Med 2009;360: Genetic Effects on Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel Mega JL, et al. N Engl J.
Morning blood pressure surge (A), HR increase in the morning (B), cfPWV (C), sympathetic BRS (D), and cardiovagal BRS (E) in elderly hypertensive subjects.

Morning blood pressure surge (A), HR increase in the morning (B), cfPWV (C), sympathetic BRS (D), and cardiovagal BRS (E) in elderly hypertensive subjects.
Fig. 1.  CsA blood concentration time curve according to the population model (dashed line), the actual measured CsA blood concentrations at t=0, 2 and.

Fig. 1.  CsA blood concentration time curve according to the population model (dashed line), the actual measured CsA blood concentrations at t=0, 2 and.
Volume 9, Issue 8, Pages (August 2017)

Volume 9, Issue 8, Pages (August 2017)
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.

Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
Checklist for Site Reconnaissance (Sabatini et al_2002)

Checklist for Site Reconnaissance (Sabatini et al_2002)
שאילת שאלות מקדמות למידה

שאילת שאלות מקדמות למידה
Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain  I.

Fentanyl HCl iontophoretic transdermal system (ITS): clinical application of iontophoretic technology in the management of acute postoperative pain  I.
Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.

Fig. 2. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral blood. Engraftment of CART-EGFRvIII and cytokine modulation in the peripheral.
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects 

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects 
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects 

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects 
IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.
Receiver operating characteristic curves with statistical significance are shown. Receiver operating characteristic curves with statistical significance.

Receiver operating characteristic curves with statistical significance are shown. Receiver operating characteristic curves with statistical significance.
Normalized and averaged images of rGMC and I-123 iomazenil BP

Normalized and averaged images of rGMC and I-123 iomazenil BP
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Similar presentations

Ads by Google